ERAS Stock: Erasca, Inc. Stock Price, Analysis & Insights
Get live ERAS stock price $13.41, comprehensive Erasca, Inc. stock analysis, charts, news, and expert forecast. Real-time ERAS stock data and investment insights.
Loading chart data...
Investment Score
A systematic tri-factor framework that integrates valuation, business quality, and market momentum into one investment signal. This helps investors triage opportunities faster, while surfacing risk regimes that may require tighter position sizing or deeper due diligence.
Score unavailable for this asset.
0-39
Defensive posture
40-54
Mixed / wait for confirmation
55-69
Constructive setup
70-100
Attractive zone
Total Score
Value
Cheapness vs fundamentals and cash generation
Quality
Durability of profitability and balance sheet
Momentum
Price trend strength and persistence
Company Overview
Erasca, Inc. is a biopharmaceutical company in the clinical development stage, primarily focused on identifying, advancing, and commercializing therapeutic solutions for malignancies propelled by the RAS/MAPK pathway. The firm's pipeline features sev...
Company Information
- CEO
- Jonathan E. Lim
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 103
Contact Information
- Website
- https://www.erasca.com
- Address
- 10835 Road to the Cure
- Country
- US
Investment Analysis & Business Insights
Investment Highlights
✓ Strong presence in the Healthcare sector with established market position
✓ Lower volatility stock (Beta: 0.73) may provide portfolio stability
Important Investment Considerations
- ⚠All investments carry risk, including potential loss of principal for Erasca, Inc. shareholders
- ⚠Market volatility can significantly impact stock price, especially for smaller companies
- ⚠Sector-specific risks in Healthcare may affect company performance
- ⚠Past performance does not guarantee future results for Erasca, Inc.
- ⚠Investors should consider how Erasca, Inc. fits within their overall portfolio allocation
- ⚠Valuation metrics suggest potential, but require fundamental analysis
Market Cap
4.17B
P/E Ratio (TTM)
-14.42
Beta
0.73
Data Sources & Methodology
Financial data on this page is sourced from verified SEC EDGAR filings (10-K, 10-Q, 8-K reports), real-time market data providers, and official company disclosures. All analysis is generated using AI models trained exclusively on reliable financial documents. For detailed information about our data sources and methodology, see our Methodology page.Not investment advice.
Related Stocks
Compare ERAS with peer companies:
- Price
- $7.21
- Market cap
- 465.20M
- Price
- $12.58
- Market cap
- 718.13M
- Price
- $30.55
- Market cap
- 1.42B
- Price
- $11.17
- Market cap
- 939.29M
- Price
- $2.98
- Market cap
- 479.25M
- Price
- $3.88
- Market cap
- 1.39B
- Price
- $29.87
- Market cap
- 1.00B
- Price
- $9.21
- Market cap
- 852.93M
- Price
- $17.80
- Market cap
- 1.31B
- Price
- $5.31
- Market cap
- 472.89M
About Healthcare Sector
The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.